EC Number   |
Application |
Reference |
|---|
   2.4.1.227 | biotechnology |
MurG is interesting to evaluate as a potential antibiotic target, as it has no counterpart in mammalian cells |
-, 676084 |
| 2.4.1.227 | drug development |
MurG is a target for development of antibacterial agents |
721824 |
| 2.4.1.227 | drug development |
MurG is a target for drug development to treat diseases caused by Clostridium difficile, an etiologic agent of a variety of gastrointestinal diseases in humans including mild sporadic diarrhea and severe life-threatening pseudomembranous colitis |
-, 723086 |
| 2.4.1.227 | drug development |
the enzyme is an important and unique drug target in Acinetobacter baumannii since it plays a key role during the synthesis of peptidoglycan and it is not found in Homo sapiens. In-silico based exploring of potential lead candidates from the library of natural products for the treatment of Acinetobacter baumannii infections is accomplished with the aid of systematic computational analysis. A 3D model of MurG is predicted using comparative protein modeling approach based on homologous MurG structure from Escherichia coli (strain K12) (PDB ID: 1F0K). Concordance binding site analysis is performed to identify the putative ligand binding sites of optimized MurG model for virtual screening and docking studies against natural compounds subset of Zinc database |
-, 759512 |
| 2.4.1.227 | synthesis |
overexpression of enzyme results in formation of vesicular intracellular membranes enriched in cardiolipin. Cardiolipin content of cell is about 7fold increased |
659026 |
